Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Vaccine ; 32(11): 1240-6, 2014 Mar 05.
Article in English | MEDLINE | ID: mdl-24486361

ABSTRACT

The hepatitis B virus continues to be a major pathogen worldwide despite the availability of an effective parenteral vaccine for over 20 years. Orally-delivered subunit vaccines produced in maize may help to alleviate the disease burden by providing a low-cost, heat-stable alternative to the parenteral vaccine. Oral subunit vaccination has been an elusive goal due to the large amounts of antigen required to induce an immunologic response when administered through the digestive tract. Here we show that high levels of HBsAg were obtained in maize grain, the grain was formed into edible wafers, and wafers were fed to mice at a concentration of approximately 300 µg/g. When these wafers were made with supercritical fluid extraction (SFE)-treated maize material, robust IgG and IgA responses in sera were observed that were comparable to the injected commercial vaccine (Recombivax(®)). In addition, all mice administered SFE wafers showed high secretory IgA titers in fecal material whereas Recombivax(®) treated mice showed no detectable titer. Increased salivary IgA titers were also detected in SFE-fed mice but not in Recombivax(®) treated mice. Wafers made from hexane-treated or full fat maize material induced immunologic responses, but fecal titers were attenuated relative to those produced by SFE-treated wafers. These responses demonstrate the feasibility of using a two-dose oral vaccine booster in the absence of an adjuvant to induce immunologic responses in both sera and at mucosal surfaces, and highlight the potential limitations of using an exclusively parenteral dosing regime.


Subject(s)
Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/immunology , Immunity, Mucosal , Plants, Genetically Modified/metabolism , Administration, Oral , Animals , Chromatography, Supercritical Fluid , Hepatitis Antibodies/blood , Hepatitis B Surface Antigens/biosynthesis , Immunoglobulin A/blood , Immunoglobulin A, Secretory/immunology , Immunoglobulin G/blood , Mice , Mice, Inbred BALB C , Vaccines, Subunit/immunology , Vaccines, Synthetic/immunology , Zea mays/genetics , Zea mays/metabolism
2.
Plant Biotechnol J ; 10(8): 979-84, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22816734

ABSTRACT

Plant-based oral vaccines are a promising emergent technology that could help alleviate disease burden worldwide by providing a low-cost, heat-stable, oral alternative to parenterally administered commercial vaccines. Here, we describe high-level accumulation of the hepatitis B surface antigen (HBsAg) at a mean concentration of 0.51%TSP in maize T1 seeds using an improved version of the globulin1 promoter. This concentration is more than fourfold higher than any previously reported lines. HBsAg expressed in maize seeds was extremely heat stable, tolerating temperatures up to 55 °C for 1 month without degradation. Optimal heat stability was achieved after oil extraction of ground maize material, either by supercritical fluid extraction or hexane treatment. The contributions of this material towards the development of a practical oral vaccine delivery system are discussed.


Subject(s)
Hepatitis B Surface Antigens/biosynthesis , Hepatitis B Vaccines/biosynthesis , Plants, Genetically Modified/metabolism , Seeds/chemistry , Zea mays/immunology , Hepatitis B Surface Antigens/analysis , Plant Extracts/analysis , Plant Extracts/immunology , Plant Oils/analysis
3.
Vaccine ; 30(19): 2937-42, 2012 Apr 19.
Article in English | MEDLINE | ID: mdl-22406456

ABSTRACT

Hepatitis B remains a major global health problem despite the availability of a safe and effective vaccine. Segments of the population lack access to or respond poorly to the parenteral vaccine, perpetuating the infection-transmission cycle. A low cost, orally delivered vaccine has the potential to alleviate many of these problems. Here we describe the expression of a bioencapsulated hepatitis B surface antigen (HBsAg) in maize and its immunogenicity, demonstrating for the first time a commercially feasible oral subunit vaccine production system for a major disease. This work surmounts previous barriers to plant-produced vaccines by expressing HBsAg at much higher levels and retaining antigen immunogenicity post-processing: factors which facilitated a robust immune response in mice without the need for an adjuvant. This method provides a practical solution to the delivery of a low-cost, stable oral vaccine.


Subject(s)
Drug Delivery Systems , Hepatitis B Surface Antigens/administration & dosage , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/administration & dosage , Hepatitis B Vaccines/immunology , Administration, Oral , Animals , Antibodies, Viral/blood , Mice , Mice, Inbred BALB C , Vaccines, Edible/administration & dosage , Vaccines, Edible/immunology , Zea mays/genetics , Zea mays/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...